57 related articles for article (PubMed ID: 3070932)
1. [Immunosorption method of urokinase determination].
Isachenkov VA; Vakulina OP; Tomilin VA
Vopr Med Khim; 1988; 34(6):133-6. PubMed ID: 3070932
[TBL] [Abstract][Full Text] [Related]
2. Human articular cartilage contains an inhibitor of plasminogen activator.
Yamada H; Stephens RW; Nakagawa T; McNicol D
J Rheumatol; 1988 Jul; 15(7):1138-43. PubMed ID: 3139880
[TBL] [Abstract][Full Text] [Related]
3. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
Grøndahl-Hansen J; Agerlin N; Munkholm-Larsen P; Bach F; Nielsen LS; Dombernowsky P; Danø K
J Lab Clin Med; 1988 Jan; 111(1):42-51. PubMed ID: 3121772
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
5. Changes in pericardial morphology and fibrinolytic activity during cardiopulmonary bypass.
Nkere UU; Whawell SA; Thompson EM; Thompson JN; Taylor KM
J Thorac Cardiovasc Surg; 1993 Aug; 106(2):339-45. PubMed ID: 8341074
[TBL] [Abstract][Full Text] [Related]
6. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.
Wilson MJ; Ludowese C; Sinha AA; Estensen RD
Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400
[TBL] [Abstract][Full Text] [Related]
7. Preparation (agar zone electrophoresis) and immunological characterisation of urokinase.
Andrassy K; Ritz E
Thromb Haemost; 1977 Aug; 38(2):536-44. PubMed ID: 579494
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
Anticancer Res; 2000; 20(5C):3975-81. PubMed ID: 11268487
[TBL] [Abstract][Full Text] [Related]
9. Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms.
Falkenberg M; Holmdahl L; Tjärnström J; Risberg B
Eur J Surg; 2001 Jan; 167(1):10-4. PubMed ID: 11213813
[TBL] [Abstract][Full Text] [Related]
10. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase.
Kruithof EK; Tran-Thang C; Bachmann F
Thromb Haemost; 1986 Feb; 55(1):65-9. PubMed ID: 3085266
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
12. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous determination of free tissue-type and free urokinase-type plasminogen activators in biological fluids by a solid-phase immunoassay.
Kuo BS; Bjornsson TD
Anal Biochem; 1993 Feb; 209(1):70-8. PubMed ID: 8465964
[TBL] [Abstract][Full Text] [Related]
14. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies.
Darras V; Thienpont M; Stump DC; Collen D
Thromb Haemost; 1986 Dec; 56(3):411-4. PubMed ID: 3105111
[TBL] [Abstract][Full Text] [Related]
15. [The effect of urokinase inhibitors on effective fibrinolytic activity of human urine].
Potapenko VE; Shataeva LK
Vopr Med Khim; 1994; 40(1):37-8. PubMed ID: 8122409
[TBL] [Abstract][Full Text] [Related]
16. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma.
Huisman LG; van Griensven JM; Kluft C
Thromb Haemost; 1995 Mar; 73(3):466-71. PubMed ID: 7667830
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.
Nielsen LS; Andreasen PA; Grøndahl-Hansen J; Huang JY; Kristensen P; Danø K
Thromb Haemost; 1986 Apr; 55(2):206-12. PubMed ID: 3520936
[TBL] [Abstract][Full Text] [Related]
19. Blood urokinase plasminogen activator system in chronic urticaria.
Kasperska-Zajac A; Brzoza Z; Rogala B
Arch Dermatol Res; 2007 Jan; 298(8):409-11. PubMed ID: 17102952
[TBL] [Abstract][Full Text] [Related]
20. Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
Koelbl H; Kirchheimer JC; Tatra G; Christ G; Binder BR
Obstet Gynecol; 1988 Aug; 72(2):252-6. PubMed ID: 3134631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]